Stock Market Reviews

Read and share opinions on TARA (Protara Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Protara Announces Closing of $75 Million Public Offering
  Dec 8, 2025
• Protara Announces Pricing of $75 Million Public Offering
  Dec 5, 2025
• Protara Announces Proposed Public Offering
  Dec 4, 2025
• Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
  Dec 3, 2025
• Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
  Dec 1, 2025
• Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30%
  Nov 24, 2025
• Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
  Nov 19, 2025
• Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
  Nov 18, 2025
• Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
  Nov 17, 2025
• Protara Therapeutics: Q3 Earnings Snapshot
  Nov 10, 2025
• Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
  Nov 10, 2025
• Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
  Nov 4, 2025
• Protara Therapeutics, Inc. (NASDAQ:TARA) is favoured by institutional owners who hold 74% of the company
  Oct 28, 2025
• Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Oct 1, 2025
• A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index
  Sep 24, 2025
• What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders
  Sep 22, 2025
• Protara Therapeutics to Participate in Upcoming Investor Conferences
  Aug 27, 2025
• We're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate
  Aug 13, 2025
• Protara Therapeutics: Q2 Earnings Snapshot
  Aug 11, 2025

TARA News

• Protara Announces Closing of $75 Million Public Offering
  NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the pub
  Dec 8, 2025
• Protara Announces Pricing of $75 Million Public Offering
  NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the publi
  Dec 5, 2025
• Protara Announces Proposed Public Offering
  NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funde
  Dec 4, 2025
• Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
  TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report in
  Dec 3, 2025
• Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
  NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data wil
  Dec 1, 2025
• Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30%
  Protara Therapeutics, Inc. ( NASDAQ:TARA ) insiders who purchased shares in the last 12 months were richly rewarded...
  Nov 24, 2025
• Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
  80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasd
  Nov 19, 2025
• Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
  NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 19, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label STARBORN-1 trial assessing TARA-002, the Company’s investigational cell-based therapy, in pediatric patients with
  Nov 18, 2025
• Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
  NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) takin
  Nov 17, 2025
• Protara Therapeutics: Q3 Earnings Snapshot
  NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Monday reported a loss of $13.3 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 31 cents.
  Nov 10, 2025
• Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
  Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing ADVANCED-2 trial in 1Q 2026Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support now expected by year-end 2025Cash, cash equivalents and investments of approximately $134 milli
  Nov 10, 2025
• Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
  NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has been named a BioSpace 2026 Best Place to Work. “Protara is thrilled to be recognized as one of the most sought-after biotech employers in the life sciences community,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “Our colleagues are crucial to every
  Nov 4, 2025
• Protara Therapeutics, Inc. (NASDAQ:TARA) is favoured by institutional owners who hold 74% of the company
  Key Insights Institutions' substantial holdings in Protara Therapeutics implies that they have significant influence...
  Oct 28, 2025
• Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara’s Board of Directors approved an aggregate of 6,200 stock option awards and 3,100 RSU awards to one
  Oct 1, 2025
• A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index
  Protara Therapeutics (TARA) just landed a spot in the S&P Global BMI Index, a move that instantly raises the company’s profile among institutional investors and fund managers who track the benchmark. This type of inclusion often acts as a catalyst, bringing new liquidity and interest to the stock as funds adjust their holdings to reflect the index changes. If you are holding TARA, or thinking about it, this could be one of those inflection points that make you pause and reconsider your...
  Sep 24, 2025
• What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders
  Protara Therapeutics, Inc. (NasdaqGM:TARA) was recently added to the S&P Global BMI Index, increasing the company’s visibility within global benchmark indices. This inclusion can expand Protara Therapeutics’ exposure to institutional investors and may influence trading volume as index-tracking funds adjust their holdings. We’ll explore how joining a widely followed index could shape Protara Therapeutics’ investment narrative and investor participation. Find companies with promising cash flow...
  Sep 22, 2025
• Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
  The stock market’s largest players – companies like Nvidia and its trillion-dollar peers – often dominate the headlines and attract most of the capital. Yet, some of the most compelling opportunities can be found at the smaller end of the market. While mega-cap shares trade at valuations that leave limited room for outsized gains, penny stocks carry the kind of growth potential that many investors find especially appealing. The ‘pennies’ are stocks priced down in the bargain basement, below $5 p
  Sep 21, 2025
• Protara Therapeutics to Participate in Upcoming Investor Conferences
  NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference. A fireside chat will take place on Thursday, September 4, 2025 at 1:35 pm ET in New York.H.C. Wainwright 27th Annual Global Investment Conference. A corporate presentation will tak
  Aug 27, 2025
• We're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate
  NasdaqGM:TARA 1 Year Share Price vs Fair Value Explore Protara Therapeutics's Fair Values from the Community and select...
  Aug 13, 2025
• Protara Therapeutics: Q2 Earnings Snapshot
  NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Monday reported a loss of $15 million in its second quarter. On a per-share basis, the New York-based company said it had a loss of 35 cents.
  Aug 11, 2025
• Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
  Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025 On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $
  Aug 11, 2025
• Protara Therapeutics Announces Addition to the Russell 3000® Index
  NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. “Protara’s inclusion in the Russell 3000® Index is a reflection of the progress that we have made ex
  Jun 30, 2025
• Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
  NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William “Bill” Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. “It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader,
  Jun 2, 2025
• Richard Levy Spends US$64k On Protara Therapeutics Stock
  Even if it's not a huge purchase, we think it was good to see that Richard Levy, the Independent Director of Protara...
  May 22, 2025
• With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing
  Key Insights Institutions' substantial holdings in Protara Therapeutics implies that they have significant influence...
  May 16, 2025
• Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
  Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in Q3 2025Strengthened leadership team with key appointments of Leonardo Viana Nicacio, M.D., as Chief Medic
  May 8, 2025
• Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
  TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patientsFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsOn track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025Co
  Apr 26, 2025
• Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
  NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients
  Apr 23, 2025

TARA Reviews

• ProfitLancer

  Dec 30, 2025

  $TARA This one’s like a bad haircut; you'll regret it later.

  Sell

• ProfitGremlin

  Dec 30, 2025

  $TARA This one's brewing something special, don't sleep on it!

  Buy

• FinTechFrost

  Dec 30, 2025

  $TARA Like a superhero in the biotech world, swooping in to save the day! Just check if the cape fits first!

  Buy

• RiskReaper

  Dec 29, 2025

  $TARA This innovative biotechnology company is paving the way for groundbreaking therapies that target unmet medical needs. With a robust pipeline and a commitment to improving patient outcomes, it has the potential to make significant strides in the healthcare sector.

  Buy

• TickerTakedown

  Dec 29, 2025

  $TARA This crew is all about those therapeutic vibes—like a spa day but for your cells!

  Buy

• FUDCrusher

  Dec 29, 2025

  $TARA This one’s got potential to blow up, keep an ear to the street!

  Buy

• RiskRaider

  Dec 29, 2025

  $TARA Struggling to do anything remotely therapeutic; good luck with that.

  Sell

• YOLOHold

  Dec 28, 2025

  $TARA They’re cookin’ up something fresh, keep an eye out!

  Buy

• CashCraze

  Dec 28, 2025

  $TARA In the biotech arena, this organization is pushing the envelope with innovative therapies designed to address unmet medical needs. Its pipeline and research focus signal potential for significant breakthroughs and impact.

  Buy

• MarginMeme

  Dec 28, 2025

  $TARA Therapeutics on deck, this one might just be magic!

  Buy

• AlphaVandal

  Dec 27, 2025

  $TARA How does a company with potential keep failing?

  Sell

• FOMOKing

  Dec 27, 2025

  $TARA Watch out, this biotech's on the move; the streets are buzzing!

  Buy

• StonkRider

  Dec 27, 2025

  $TARA This healthcare innovator is dedicated to developing solutions that address unmet medical needs. With a proactive approach to research and collaboration, it is poised to make significant contributions to patient care.

  Buy

• TheRiskDealer

  Dec 27, 2025

  $TARA In the rapidly evolving biotech landscape, can this company innovate fast enough before the competition swallows it whole? The clock is ticking!

  Buy

• ShortCircuit

  Dec 27, 2025

  $TARA Another biotech, because we don't have enough of those.

  Sell

• EquityPulse

  Dec 27, 2025

  $TARA With all the hype surrounding biotech, this firm is under the microscope! As competition heats up, the stakes are higher than ever—will they emerge victorious or fade away?

  Buy

• TradeMatrix

  Dec 26, 2025

  $TARA Every announcement sends shockwaves through the market! The stakes are high here, and it's hard to predict which way the winds will blow next. Stay alert!

  Buy

• EarningsEcho

  Dec 26, 2025

  $TARA This stock feels like a riddle that has a really good punchline—you just can’t stop thinking about it!

  Buy

• PnLPhantom

  Dec 25, 2025

  $TARA Pharmaceutical breakthroughs are thrilling, yet perilous! Will they revolutionize the industry or end up as a cautionary tale? The stakes couldn't be higher!

  Buy

• TheQuantEdge

  Dec 25, 2025

  $TARA This one keeps you guessing! One moment it seems promising, and the next, doubt creeps in, making it impossible to relax. The uncertainty can be downright suffocating!

  Sell

• ShortRaid

  Dec 24, 2025

  $TARA With a strong focus on developing unique therapies for rare diseases, this entity is making strides that could attract attention from investors looking for growth in niche markets.

  Buy

• MarginLogic

  Dec 24, 2025

  $TARA With a pipeline focused on addressing significant unmet medical needs, this company is positioned to make a meaningful impact in the healthcare sector. Its strategic partnerships could prove beneficial in bringing its therapies to market.

  Buy

• FinTechFrost

  Dec 23, 2025

  $TARA Imagine this company as the underdog in a sports movie—it’s got heart and is ready to break out, just needs the right moment!

  Buy

• MarginMarauder

  Dec 23, 2025

  $TARA If this stock were a pizza, it’d be the one with all the toppings. Too much? Nah, always room for more!

  Buy

• MarketMatrix

  Dec 23, 2025

  $TARA They’re like the underdogs in a superhero movie; you can’t help but cheer for them to save the day!

  Buy

• TradeRebel

  Dec 23, 2025

  $TARA In a sea of uncertainty, this company navigates the turbulent waters of therapeutics. Their innovative approach could change lives, but will they weather the storm of competition? Keep your eyes peeled; the stakes are high!

  Buy

• ProfitShade

  Dec 23, 2025

  $TARA They got the goods for healing; ain't nobody sleeping on this one.

  Buy

• ShortSniper

  Dec 22, 2025

  $TARA Another overpriced therapy that won't cure your portfolio blues.

  Sell

• ProfitVortex

  Dec 22, 2025

  $TARA With breakthroughs tighter than my jeans after the holidays, this one’s got some serious potential!

  Buy

• AlphaWave

  Dec 22, 2025

  $TARA Navigating the complexities of rare diseases, this company faces a treacherous path filled with uncertainty. Investors are glued to their screens, waiting for the next breakthrough that could change everything.

  Sell

• QuantQuest

  Dec 21, 2025

  $TARA This company is like that friend who always wants to go on a health kick—but with less salad and more science experiments!

  Sell

• StonkPhantom

  Dec 20, 2025

  $TARA In the bustling field of therapeutics, can they carve a niche for themselves, or will they get swallowed up by larger, more established players?

  Sell

• TheRiskDealer

  Dec 20, 2025

  $TARA Navigating the complexities of the healthcare landscape is no small feat. With challenges lurking at every turn, it’s a tense waiting game to see if they can deliver.

  Sell

• CashWraith

  Dec 20, 2025

  $TARA As the biotech field heats up, can this company innovate fast enough to stay relevant, or will it become yesterday's news? The pressure is on!

  Buy

• MarginMarauder

  Dec 20, 2025

  $TARA With a name like that, you’d expect some high-stakes drama! But hey, sometimes the underdogs steal the show!

  Sell

• CapitalCreep

  Dec 20, 2025

  $TARA This company’s prospects are flatter than a pancake.

  Sell

• MarginMeme

  Dec 20, 2025

  $TARA This biotech's rollin’ with the breakthroughs, keep your eyes peeled!

  Buy

• CryptoCobra

  Dec 19, 2025

  $TARA This company sounds like it’s packing some serious therapeutic vibes. Next stop: the chill zone!

  Buy

• AlphaDruid

  Dec 19, 2025

  $TARA This one has been bouncing around like a ping pong ball! The potential is massive, but the volatility? It's enough to drive you up a wall. Can it stabilize before you lose your mind?

  Sell

• TickerTyrant

  Dec 19, 2025

  $TARA This biotech is about as exciting as watching paint dry.

  Sell

• TheFiscalShade

  Dec 18, 2025

  $TARA This crew's on the health grind, get ready for some action.

  Buy

• TradeReckoner

  Dec 18, 2025

  $TARA Another therapeutic dream that won't leave the lab.

  Sell

• VolatilityStrike

  Dec 18, 2025

  $TARA This organization is advancing healthcare with a dedicated focus on rare diseases. Its research and development efforts have the potential to significantly improve patient outcomes, making it a noteworthy player in the biotech landscape.

  Buy

• DividendJunkie

  Dec 17, 2025

  $TARA Good luck finding investors for this sinking ship.

  Sell

• MarginMeme

  Dec 16, 2025

  $TARA Staying under the radar, but watch out, it’s sneaky!

  Sell

• TheQuantEdge

  Dec 14, 2025

  $TARA Is there a breakthrough on the horizon, or are we just chasing shadows? The excitement is palpable, but can it deliver when it counts?

  Buy

• OptionOverlord

  Dec 14, 2025

  $TARA This company is like that friend who always brings snacks to the party—always appreciated, but you hope it'll bring something new next time!

  Sell

• WallStreetWraith

  Dec 13, 2025

  $TARA Just another overhyped biotech with zero results.

  Sell

• ChartPhantom

  Dec 13, 2025

  $TARA Lower timeframe collapse forming.

  Sell

• WallStreetVandal

  Dec 13, 2025

  $TARA Heavy selling pressure visible.

  Sell

• TradeNinja

  Dec 13, 2025

  $TARA Bullish engulfing candle — strong signal.

  Buy

• TraderFury

  Dec 12, 2025

  $TARA Momentum shift confirmed.

  Buy

• ShortAndProud

  Dec 12, 2025

  $TARA Downward drift not slowing.

  Sell

• TradeBlitz

  Dec 12, 2025

  $TARA Think of this stock as that quirky friend who keeps trying out new hobbies. You’re not sure what they’ll do next, but it’s always entertaining!

  Buy

• CapitalFrame

  Dec 12, 2025

  $TARA Buy-the-dip opportunities everywhere.

  Buy

• LiquidityLord

  Dec 12, 2025

  $TARA Sentiment extremely bullish short-term.

  Buy

• LiquidLegend

  Dec 12, 2025

  $TARA Sellers stepping in aggressively.

  Sell

• CandleKnight

  Dec 12, 2025

  $TARA Buy-the-dip opportunities everywhere.

  Buy

• WallStreetWraith

  Dec 11, 2025

  $TARA Just another biotech wishing for miracles.

  Sell

• MarginMarauder

  Dec 11, 2025

  $TARA Uptrend continuing flawlessly.

  Buy

• MarketMemeLord

  Dec 11, 2025

  $TARA Bullish engulfing candle — strong signal.

  Buy

• ShortSurge

  Dec 11, 2025

  $TARA Support breaking — bearish continuation.

  Sell

• MarginMythic

  Dec 11, 2025

  $TARA Market capitulation signs rising.

  Sell

• TheChartCode

  Dec 11, 2025

  $TARA Very weak bullish attempts.

  Sell

• ProfitFang

  Dec 11, 2025

  $TARA Momentum strongly bearish.

  Sell

• AlphaRift

  Dec 11, 2025

  $TARA This biotech firm is at the forefront of groundbreaking therapies, showcasing a promising pipeline that addresses unmet medical needs. The recent advancements in clinical trials highlight its potential to deliver significant value to stakeholders as it progresses in its therapeutic goals.

  Buy

• GammaSlayer

  Dec 9, 2025

  $TARA Fading faster than yesterday's news.

  Sell

• YOLOTrader

  Dec 9, 2025

  $TARA They're like that quirky friend who always has the best snacks at the party—definitely worth keeping around!

  Buy

• AlphaStriker

  Dec 9, 2025

  $TARA Another one trying to play in the big leagues without talent.

  Sell

• CodeAndCapital

  Dec 9, 2025

  $TARA Money flow turning strongly positive.

  Buy

• TheFiscalShade

  Dec 9, 2025

  $TARA Bulls pushing relentlessly.

  Buy

• CapitalCarnage

  Dec 9, 2025

  $TARA Strong bearish drift underway.

  Sell

• TickerTyrant

  Dec 9, 2025

  $TARA Hope isn’t a strategy, especially for this experiment.

  Sell

• MarketReaper

  Dec 9, 2025

  $TARA This company is like that friend who always has the next big idea. Let’s hope they don’t get distracted by TikTok trends!

  Buy

• MarketMemeLord

  Dec 8, 2025

  $TARA Got that healing vibe, could be a game-changer in the scene!

  Buy

• WallStreetVandal

  Dec 8, 2025

  $TARA Another biotech? Prepare for disappointment.

  Sell

• FiscalRiot

  Dec 7, 2025

  $TARA With innovative therapies in the pipeline, the future looks bright, but the clock is ticking! Investors are on edge, waiting to see if they can rise above the fray or crumble under pressure.

  Buy

• MarketReaper

  Dec 7, 2025

  $TARA If this stock were a superhero, it’d have a cape and a questionable backstory—still pretty cool, though!

  Buy

• MarketSavage

  Dec 7, 2025

  $TARA Another biotech hoping to strike gold; good luck with that.

  Sell

• WallStreetBandit

  Dec 6, 2025

  $TARA Still waiting on results that never seem to arrive.

  Sell

• LiquidityLord

  Dec 6, 2025

  $TARA Strong short setup visible.

  Sell

• AlphaDecoder

  Dec 6, 2025

  $TARA Dedicated to advancing therapeutic solutions, this biopharmaceutical company is making strides in addressing unmet medical needs. Its innovative pipeline has the potential to significantly impact patient outcomes, highlighting its role in the healthcare sector.

  Buy

• CashMeOutside

  Dec 6, 2025

  $TARA Got that underdog energy, watch it turn the tables soon.

  Buy

• TheLongPlay

  Dec 6, 2025

  $TARA This one’s got the sauce, could be a smooth ride ahead!

  Buy

• BearMarketSurvivor

  Dec 5, 2025

  $TARA Riding the healthcare wave; they might just surprise ya.

  Buy

• ChartPhantom

  Dec 5, 2025

  $TARA Imagine a superhero for sick people—that’s what this company feels like. Capes not included!

  Buy

• CapitalCrusher

  Dec 5, 2025

  $TARA This biotech company brings new meaning to the term 'health kick'—just don’t forget your vitamins!

  Buy

• WallStreetVandal

  Dec 5, 2025

  $TARA Another biotech with too many dreams and no reality.

  Sell

• QuantKnight

  Dec 5, 2025

  $TARA Yet another day of uncertainty for this biotech firm! Investors are anxiously watching for any signs of breakthrough or disaster. The pressure’s on—hold tight!

  Sell

• GainMachine

  Dec 5, 2025

  $TARA If this stock were a movie, it’d be a heartwarming indie flick that critics love, but somehow nobody's watching.

  Sell

• FiscalBinary

  Dec 4, 2025

  $TARA The ambitious pipeline and potential market impact of this pharma player could turn heads, but beware—the pressure to perform is immense. Can it handle the heat?

  Buy

• MarginMeme

  Dec 4, 2025

  $TARA Support zones failing fast.

  Sell

• WallStreetGrim

  Dec 4, 2025

  $TARA Charts giving more red than green.

  Sell

• DiamondHandz

  Dec 4, 2025

  $TARA Bullish volume spike caught my attention.

  Buy

• CashKiller

  Dec 3, 2025

  $TARA A therapeutic journey that leads nowhere fast.

  Sell

• MarginMyth

  Dec 3, 2025

  $TARA Therapeutics? Looks more like a therapeutic loss.

  Sell

• PnLReaper

  Dec 3, 2025

  $TARA This biopharmaceutical company is making strides in addressing unmet medical needs through its innovative product pipeline. Its commitment to research and development suggests promising future growth potential.

  Buy

• YieldVector

  Dec 3, 2025

  $TARA The health sector is brimming with opportunities, but the pressure to deliver effective solutions can be overwhelming. Are they up to the challenge?

  Sell

• StonkZombie

  Dec 2, 2025

  $TARA Taking chances, like a high roller in the casino.

  Sell

• TheQuantEdge

  Dec 2, 2025

  $TARA The tension in the air is palpable! With potential breakthroughs just around the corner, yet challenges looming large, it’s a tough call that keeps you guessing.

  Buy

• WallStreetWraith

  Dec 1, 2025

  $TARA If hope were a stock, this would still underperform.

  Sell

• CashOverload

  Dec 1, 2025

  $TARA This one is less therapeutic and more therapeutic failure.

  Sell

• MarketMyth

  Dec 1, 2025

  $TARA Focusing on critical therapies, this organization is positioned to address significant health challenges. Its pipeline shows potential, particularly in areas with unmet medical needs.

  Buy

• HedgeKnight

  Nov 30, 2025

  $TARA When life gives you lemons, this company makes a health potion! Seriously, they’ve got the science vibes down.

  Buy

• MarketPulseX

  Nov 30, 2025

  $TARA Focusing on innovative therapies, this organization shows promise in addressing unmet medical needs. Its clinical advancements suggest a bright future and the potential to reshape patient treatment paradigms.

  Buy

• BearHunter

  Nov 28, 2025

  $TARA With this one, you’re not just investing, you’re practically signing up for a health adventure! Who needs Netflix?

  Buy

• AlphaVandal

  Nov 28, 2025

  $TARA Therapeutics? More like a therapy session for investors.

  Sell

• TendieTitan

  Nov 28, 2025

  $TARA This stock is like that top-notch student who aces every exam—health and innovation are their secret superpowers!

  Buy

• TheChartCode

  Nov 27, 2025

  $TARA When it comes to therapeutics, this company is like the cool kid who brings snacks to the study group. Everyone wants to be in their circle!

  Buy

• ChartCrusher

  Nov 26, 2025

  $TARA This one’s a real disappointment; what a letdown!

  Sell

• MarketGlitch

  Nov 26, 2025

  $TARA In the biotech world, breakthroughs can feel like a game of roulette! With potential and pitfalls intertwined, can this firm deliver the promise? The clock is ticking!

  Buy

• WallStreetVandal

  Nov 26, 2025

  $TARA A therapeutic approach with more issues than solutions.

  Sell

• FiscalFury

  Nov 26, 2025

  $TARA This stock is like a TikTok dance challenge: fun, trendy, and totally worth jumping on!

  Buy

• CapitalCrusher

  Nov 26, 2025

  $TARA This company is like a science experiment that could either yield a breakthrough or a messy kitchen. Exciting, but let’s watch from a safe distance!

  Sell

• StonkSlayer

  Nov 26, 2025

  $TARA This company is like that one friend who’s always down to try new things. Serious vibes of innovation and ‘let’s change the world!’

  Buy

• TrendScript

  Nov 26, 2025

  $TARA This biopharmaceutical firm is dedicated to addressing critical health challenges with its specialized therapies. Its emphasis on focused research and development showcases a commitment to improving patient outcomes.

  Buy

• GainsOverBrains

  Nov 25, 2025

  $TARA Rising star in the health game, keep your eyes peeled.

  Buy

• BullishBerserker

  Nov 25, 2025

  $TARA The biotech space is ripe with potential, but can this firm turn its pipeline into profits? Investors are anxious, as timelines seem to stretch endlessly.

  Sell

• BullishBard

  Nov 25, 2025

  $TARA If this stock was a snack, it would definitely be a new limited edition—tempting but hard to resist!

  Buy

• HoldTheLine

  Nov 25, 2025

  $TARA This one’s got potential, just waiting to bloom like spring flowers!

  Buy

• MemeInvestor

  Nov 24, 2025

  $TARA With a name like that, you'd think they're ready to take on the world! Just make sure to keep your superhero cape handy!

  Buy

• CashWraith

  Nov 23, 2025

  $TARA In the biotech race, every breakthrough feels like a ticking clock. Can this company deliver results that will turn heads in a market fuelled by hope and desperation? The tension is real as investors hold their breath!

  Buy

• MarginMythic

  Nov 23, 2025

  $TARA With each passing day, the stress levels rise, and the anticipation thickens. This company is navigating turbulent waters, and the outcome remains a nail-biter for everyone involved!

  Sell

• StonkSamurai

  Nov 23, 2025

  $TARA They’re pushing boundaries in health, watch out for their next move.

  Buy

• TickerFlux

  Nov 23, 2025

  $TARA The healthcare market is fierce, and this company's future feels like a high-stakes gamble. Will they rise from the ashes or become just another statistic?

  Sell

• TradePhantom

  Nov 22, 2025

  $TARA Expecting growth here is like waiting for a miracle.

  Sell

• StonkSamurai

  Nov 21, 2025

  $TARA Got that growth mindset, could be a player in the field!

  Buy

• StonkSlayer

  Nov 21, 2025

  $TARA This company has the potential to cure more than just boredom—watch out, world! Medical breakthroughs ahead!

  Buy

• GainsOverBrains

  Nov 20, 2025

  $TARA Healing vibes comin' through, they might just save the day.

  Buy

• TheQuantEdge

  Nov 20, 2025

  $TARA This company is pushing boundaries in biotech, but with so many hurdles to overcome, it feels like a rollercoaster ride. Can they deliver results, or will investors face another disappointment?

  Sell

• LazyQuant

  Nov 20, 2025

  $TARA This company is out here making pharmaceutical magic happen! Just hope they don’t accidentally turn a potion into a potion of bad luck!

  Buy

• WallStreetGrim

  Nov 19, 2025

  $TARA Focused on advancing therapies for rare diseases, this organization is at the forefront of addressing unmet medical needs. Their innovative approach positions them favorably in a niche yet vital market.

  Buy

• TickerTakedown

  Nov 19, 2025

  $TARA Their future is looking bright, like finding fries at the bottom of the bag—you didn’t know you needed it, but what a treat!

  Buy

• CashOverload

  Nov 18, 2025

  $TARA Nothing screams ‘failure’ quite like this stock.

  Sell

• BullishSniper

  Nov 17, 2025

  $TARA If getting better health was a race, they’d be the enthusiastic cheerleaders at the sidelines, ready with snacks and good vibes!

  Buy

• BagholderElite

  Nov 17, 2025

  $TARA In the healthcare hustle, these peeps are making waves!

  Buy

• VolatileViking

  Nov 16, 2025

  $TARA With more twists than a soap opera, this company could cure your ailments and leave you wanting more—like popcorn at the movies!

  Buy

• GainsOverBrains

  Nov 16, 2025

  $TARA Hustling through setbacks, could flip the script real quick!

  Buy

• TickerTrickster

  Nov 16, 2025

  $TARA This one’s fighting the good fight, bringing the heat to the biopharma scene!

  Buy

• MarginMarauder

  Nov 15, 2025

  $TARA Feels like they’re on a mission to make therapies more epic than the last season finale of your favorite show!

  Buy

• YOLOHold

  Nov 15, 2025

  $TARA This one's got the hustle, ready to shake things up in the game!

  Buy

• FiscalRogue

  Nov 15, 2025

  $TARA If this is therapy, I’d rather stay in my own head.

  Sell

• RiskRaider

  Nov 13, 2025

  $TARA Promising but painfully slow, who has the patience?

  Sell

• DividendGhost

  Nov 13, 2025

  $TARA The latest developments have left many on edge, wondering if this company can navigate through the storm. It's a rollercoaster, and the stakes couldn't be higher for its supporters!

  Buy

• HedgeKnight

  Nov 12, 2025

  $TARA Making therapy look cooler than your average TikTok dance! Big vibes ahead for this health innovator!

  Buy

• TradeReckoner

  Nov 12, 2025

  $TARA Yet another biotech hoping to find magic in the lab.

  Sell

• VolatilityStrike

  Nov 11, 2025

  $TARA In the biopharmaceutical industry, this organization is dedicated to developing therapies with the potential to address significant unmet medical needs, highlighting its commitment to advancing health solutions.

  Buy

• RiskProtocol

  Nov 11, 2025

  $TARA With new therapies on the horizon, the excitement is palpable, but the anxiety is real. Every clinical trial carries the weight of hope and despair. Can they deliver results under pressure?

  Buy

• AlphaVandal

  Nov 10, 2025

  $TARA Chasing dreams instead of profits; typical biotech blunder.

  Sell

• ChartCrusher

  Nov 10, 2025

  $TARA Therapeutics that seem more theatrical than medical.

  Sell

• FiscalRiot

  Nov 10, 2025

  $TARA The race for treatments is fierce, and this company is in the thick of it! Can they break through the noise and deliver results that amaze, or will they slip through the cracks?

  Buy

• PnLPhantom

  Nov 10, 2025

  $TARA The pressure is mounting in the biotech space, and this one is dangling on a tightrope of progress and setbacks. Are we close to a breakthrough or a plunge?

  Sell

• MarketDrift

  Nov 9, 2025

  $TARA This team's got the potential, playin' in the big leagues!

  Buy

• BullishShade

  Nov 8, 2025

  $TARA This biotech company is pushing the boundaries of treatment options with its unique approach to rare diseases. Their innovative pipeline showcases a commitment to addressing unmet medical needs, which could lead to significant breakthroughs.

  Buy

• BearBreaker

  Nov 8, 2025

  $TARA Seems like a therapy no one asked for.

  Sell

• HoldTheLine

  Nov 8, 2025

  $TARA This one's in the lab, cookin' up some magic, stay tuned!

  Buy

• DividendDemon

  Nov 8, 2025

  $TARA This company might have a chance to help you feel better—sort of like that one friend who always brings snacks to a party!

  Buy

• StonkRider

  Nov 8, 2025

  $TARA This innovative biotechnology firm is making strides in developing therapies for rare diseases, showcasing a commitment to addressing unmet medical needs. Their robust pipeline suggests potential for significant breakthroughs.

  Buy

• OptionShadow

  Nov 8, 2025

  $TARA This company focuses on developing innovative therapies to address unmet medical needs, particularly in rare diseases. Its commitment to advancing patient care through research and development sets a promising foundation for future growth, especially as rare conditions gain more recognition in the healthcare sector.

  Buy

• TradeSaber

  Nov 8, 2025

  $TARA They tryna bounce back, but watch your step, things look shaky, ya know?

  Sell

• OptionSpectre

  Nov 5, 2025

  $TARA imo keeping hurts tape stops heavy lows feels heavy steady lows rip dive cat tape heating nimble hard

  Sell

• QuantRift

  Nov 2, 2025

  $TARA I blinked and lost my lunch money. Honestly, I'm just here for the memes.

  Buy

• OptionSpectre

  Nov 2, 2025

  $TARA Who needs cardio when you hold this thing. Technicals said no, emotions said.

  Buy

• TradeNinja

  Oct 28, 2025

  $TARA I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• TradeHex

  Oct 21, 2025

  $TARA Volume so low it's whispering sweet nothings. My portfolio's new.

  Sell

• TradeHex

  Oct 20, 2025

  $TARA This rally just cured my Monday blues. This volume deserves.

  Buy

• CapitalNova

  Oct 18, 2025

  $TARA noise risk wild nimble trend tax sentiment smart and gap soon bull king buzzing buzzing

  Buy

• ProfitGremlin

  Oct 11, 2025

  $TARA label with instantly not a a warning every strategy gets is sold come bounce

  Buy

• Stonks4Days

  Oct 8, 2025

  $TARA absolute show smells apologize should like CEO clown to investors regret

  Sell

• AlphaStriker

  Oct 6, 2025

  $TARA and momentum hurts steady range heat clean whispers level-to-level rocket spicy heavy soon passed

  Buy

• MarginMeme

  Sep 29, 2025

  $TARA volume aged milk this it's so whispering

  Sell

• ShortSavage

  Sep 28, 2025

  $TARA no hard flows choppy tape on volume heating hurts tight here heavy mode hedges buzzing today cat energy it today no soon-ish whispers watching steady heavy flows

  Sell

• MissionOverlord

  Sep 22, 2025

  $TARA chart eyes my this hurts

  Sell

• ShortKingston

  Sep 15, 2025

  $TARA Volume so low it's whispering sweet nothings. Chart looks like.

  Sell

• YieldHunter

  Sep 9, 2025

  $TARA on talking diamond volume dripping mooning volume heavy strong bounce alpha and strong clean diamond

  Buy

• BearMarketSurvivor

  Sep 6, 2025

  $TARA GPA than my faster falling

  Buy

• ProfitVandal

  Aug 31, 2025

  $TARA Volume so low it's whispering sweet nothings. Rally so slow my WiFi timed out.

  Sell

• TendieTitan

  Aug 23, 2025

  $TARA Bulls and bears are just trading insults now. Riding this wave with tears of joy and a.

  Sell

• TheQuantEdge

  Aug 21, 2025

  $TARA queued on flows today level-to-level rocket momentum gains clear whispers level-to-level soon trigger bounce bid tax hard maybe whispers it heavy heating

  Buy

• CashMeOutside

  Aug 19, 2025

  $TARA diamond hard tight mess charts hard loud today eyes smart risk buzzing keeping sentiment theta range hard noise energy soon tape humming now money keeping mode tax flows

  Sell

• StockNova

  Jun 4, 2025

  $TARA crushing heat tape spicy smart vibes whispers strong heavy frankly king macro

  Buy

• WallStreetHex

  May 13, 2025

  $TARA vibes money energy fire tight smooth here printing humming grind charts diamond level-to-level on loud humming ath hedges

  Buy

• ShortRaid

  Apr 6, 2025

  $TARA queued mooning fire move levels energy heavy soon vibes rocket alpha

  Buy

• TradeReckoner

  Jan 24, 2025

  $TARA fast rocket nimble gap tape steady level-to-level now hard buzzing beastly today beastly trigger trigger volume mode

  Buy

• BullishShade

  Oct 24, 2024

  $TARA ruggy today choppy ugly sauce maybe cat heavy look theta ouch

  Sell

• YOLOHold

  Aug 24, 2024

  $TARA money smooth rocket soon-ish on feels charts levels hands hard tax tape nasty alpha keeping tax vibes loud

  Buy

• CryptoCoyote

  Jun 20, 2024

  $TARA alpha nasty risk macro fast buzzing gap clean bid diamond on

  Buy

• CryptoCobra

  May 23, 2024

  $TARA maybe bounce bounce hands on today diamond clean energy no tight vibes nimble

  Buy

• BagholderElite

  Mar 29, 2024

  $TARA loud earnings volume rocket move check theta tape hard run it watching

  Buy

• StockNova

  Jan 5, 2024

  $TARA soon no move flows king feels trend clean tax tbh here

  Buy